



Top

Biologics Manufacturing Companies in Southeast Asia 2026

Leading the Future of Biologics
Manufacturing Excellence



Insightful Rankings
Data-Driven Analysis



Industry Leaders
Pioneering Innovation



Shaping the Future
Strengthening Southeast Asia's
Biologics Ecosystem

INTRODUCTION

A region moving from pharmaceutical production to complex biologics

Southeast Asia is developing into an increasingly important location for biologics manufacturing, supported by growing healthcare demand, government investment, technology transfer and the expansion of regional biopharmaceutical capabilities.

The region is moving beyond traditional pharmaceutical production towards more sophisticated manufacturing platforms, including monoclonal antibodies, recombinant proteins, vaccines, biosimilars, antibody drug conjugates and advanced therapies.

Singapore has established itself as a major regional manufacturing hub, while Malaysia, Thailand, Indonesia and Vietnam are developing their own biologics and vaccine manufacturing capabilities.

FOR GLOBAL BIOPHARMA

Opportunities for regional manufacturing, technology transfer, CDMO partnerships and supply chain diversification.

FOR LOCAL MANUFACTURERS

The opportunity is to build the capabilities required to compete for increasingly complex biologics manufacturing programmes.

Monoclonal antibodies

Recombinant proteins

Vaccines

Biosimilars

Antibody drug conjugates

mRNA

Cell & gene therapy


Insulin

INSIDE THIS REPORT

01	Market map — where the capacity sits	03
02	The directory — 30 manufacturers by market	04
03	Why this matters	07
04	Biologics World South East Asia 2026	08

WHERE THE CAPACITY SITS

30 manufacturers across 6 ASEAN markets



SINGAPORE

The established regional hub — global drug substance, vaccine and ADC facilities alongside CDMO capacity.


MALAYSIA & THAILAND

Biosimilars, insulin and vaccine manufacturing, with a growing contract manufacturing base.

INDONESIA, VIETNAM & THE PHILIPPINES

National vaccine and biologics producers scaling towards more complex modalities.

WHAT IS BEING MADE



Counts reflect the manufacturing focus recorded for each of the 30 companies in this report; many operate across several modalities.



Singapore

10 COMPANIES



Amgen

Next-generation biologics, drug substance

HQ USA



Specialized Modalities

Lonza

mAbs, recombinant proteins, cell therapy

HQ SWITZERLAND



WuXi Biologics

Biologics CDMO, mAbs, recombinant proteins

HQ CHINA



WuXi XDC

ADCs, bioconjugates

HQ CHINA



GSK

Vaccines, vaccine antigens

HQ UK



BioNTech

mRNA / vaccine manufacturing

HQ GERMANY



Takeda

Biopharmaceutical manufacturing

HQ JAPAN



MSD

Vaccines / biologics

HQ USA



Sanofi

Vaccines / biologics

HQ FRANCE



Novartis

Biologics / biopharmaceuticals

HQ SWITZERLAND



Malaysia

4 COMPANIES



Biocon Biologics

Insulin, biosimilars, recombinant proteins

HQ INDIA



Duopharma Biotech

Biologics / biosimilars

HQ MALAYSIA



Alpha Biologics

Biologics CDMO

HQ MALAYSIA



Pharmaniaga

Vaccines / biopharmaceuticals

HQ MALAYSIA



Thailand

4 COMPANIES



Siam Bioscience

Biologics, vaccines, biosimilars

HQ THAILAND



BioNet-Asia

Vaccines / recombinant proteins

HQ THAILAND



Government Pharmaceutical Organization (GPO)

Vaccines / biological products

HQ THAILAND



Thai Red Cross / QSMI

Vaccines / biological products

HQ THAILAND

Indonesia

5 COMPANIES



Bio Farma

Vaccines / biological products

 HQ INDONESIA



Etana Biotechnologies

mRNA / biologics / vaccines

 HQ INDONESIA



Biotis Pharmaceuticals

Vaccines / biologics

 HQ INDONESIA



Kalbe Genexine Biologics

Biologics / biosimilars

 HQ INDONESIA



Daewoong Infion

Recombinant proteins / biologics

 HQ INDONESIA

Vietnam

6 COMPANIES



VABIOTECH

Vaccines / biological products

 HQ VIETNAM



IVAC

Vaccines

 HQ VIETNAM



POLYVAC

Vaccines

 HQ VIETNAM



Nanogen

Recombinant proteins / vaccines

 HQ VIETNAM



VinBioCare

Vaccines / biologics

 HQ VIETNAM



DAVAC

Vaccines

 HQ VIETNAM



Philippines

1 COMPANY



Glovax Biotech

Vaccines / biologics



HQ PHILIPPINES

WHY THIS MATTERS

The question is no longer whether capacity exists

The development of biologics manufacturing in Southeast Asia is creating a new ecosystem of manufacturers, CDMOs, technology providers and strategic partners.

It is whether Southeast Asia can develop the technology, talent, infrastructure and partnerships required to manufacture increasingly complex biologics at commercial scale.

That is where the next phase of opportunity lies.

CONNECT WITH THE REGION'S LEADERS

Meet the companies building Southeast Asia's next generation of biologics manufacturing capabilities

The companies and facilities featured in this report represent the growing manufacturing capabilities across Southeast Asia.

The next step is bringing these organisations together with the technology providers, CDMOs, pharmaceutical companies, researchers and industry leaders shaping the region's biologics ecosystem.

Biologics World South East Asia 2026

14–15 October 2026

01 Bioprocessing & Manufacturing Innovation in Southeast Asia

02 CDMO & Technology Transfer Partnerships in Southeast Asia

03 R&D, Clinical Development & Translational Science for Biologics

04 Future Modalities: ADCs, Protein Therapeutics & Advanced Biologics

05 Clinical Adoption, Reimbursement & Market Access

Join Biologics World South East Asia 2026.

Connect with the leaders, manufacturers and technology partners shaping the future of biologics across the region.

